Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure
Publication

Publications

The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure

Title
The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure
Type
Article in International Scientific Journal
Year
2009
Authors
Lourenco, P
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Araújo JP
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Azevedo A
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Ferreira A
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Bettencourt P
(Author)
FMUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Journal
Vol. 11 No. 2
Pages: 185-190
ISSN: 1388-9842
Publisher: Wiley-Blackwell
Scientific classification
FOS: Medical and Health sciences > Other medical sciences
Other information
Authenticus ID: P-003-NE1
Abstract (EN): Attenuation of the effects of natriuretic peptides has been demonstrated in animal models but studies in humans are scarce, particularly concerning renal attenuation. We investigated the attenuation of B-type natriuretic peptide (BNP) in chronic advanced heart failure (HF). We included 62 outpatients with HF and severe left ventricular systolic dysfunction. Cases had at least one hospital admission or emergency department visit for acute HF in the previous year and were in NYHA class III/IV despite optimized therapy. The individual age- and sex-matched controls were symptomatically controlled (NYHA I and II). We collected 24 h urine and a blood sample from all patients. Plasma BNP and plasma (pcGMP) and urine cyclic guanosine monophosphate (ucGMP) were measured. Patients were followed for 3 months for hospital admission or all-cause death. ucGMP to plasma BNP (ucGMP/BNP) ratio was attenuated in cases vs. controls [median (IQR): 8354 (4293-16 456) vs. 12 693 (6896-22 851)]. There were no differences in pcGMP to BNP (pcGMP/BNP) ratio or urine cGMP excretion. Patients with worse outcome had lower pcGMP/BNP [260 (86-344) vs. 381 (244-728) in patients without adverse outcome events] and lower ucGMP/BNP [4146 (2207-9363) vs. 10 922 (7495-19 971)]. Renal NP's second messenger production is attenuated in advanced HF. Patients with worse outcome have lower ucGMP/BNP and pcGMP/BNP ratios.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 6
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Prognostic Value of High-Sensitivity C-Reactive Protein in Heart Failure: A Systematic Review (2009)
Another Publication in an International Scientific Journal
Araújo JP; Lourenco, P; Azevedo A; Friões F; Rocha Goncalves, F; Ferreira A; Bettencourt P
Correlation between cholesterol levels and nutritional status in heart failure (2006)
Other Publications
Araújo JP; Azevedo A; Lourenco, P; Ferreira A; Rocha Goncalves, F; Bettencourt P
Variability of High-Sensitivity C-Reactive Protein in Chronic Heart Failure (2009)
Article in International Scientific Journal
Araújo JP; Friões F; Azevedo A; Lourenco, P; Rocha Goncalves, F; Ferreira A; Bettencourt P
Intraindividual variation of amino-terminal pro-B-type natriuretic peptide levels in patients with stable heart failure (2006)
Article in International Scientific Journal
Araújo JP; Azevedo A; Lourenco, P; Rocha Goncalves, F; Ferreira A; Bettencourt P

Of the same journal

Validation of a risk score to estimate cardiac risk in subjects from the general population on cardioactive treatment (2008)
Another Publication in an International Scientific Journal
Pimenta J; Bettencourt P; Azevedo A
Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry (2020)
Another Publication in an International Scientific Journal
Garrido¿Lestache, EB; Pinilla, JG; Villa, BG; Sahuquillo, A; Marques, RB; Calvo, FT; Perez¿Martinez, M; Gracia¿Rodenas, M; Garrido¿Bravo, IP; Pastor¿Perez, F; Pascual¿Figal, D; Molina, BD; Orus, J; Gonzalo, FE; Bertomeu, V; Valero, R; Martinez¿Abellan, R; Quiles, J; Rodrigez¿Ortega, J; Mateo, I...(mais 669 authors)
Targeting myocardial remodelling to develop novel therapies for heart failure A position paper from the Working Group on Myocardial Function of the European Society of Cardiology (2014)
Another Publication in an International Scientific Journal
Tarone, G; Balligand, JL; Bauersachs, J; Clerk, A; De Windt, L; Heymans, S; Hilfiker Kleiner, D; Hirsch, E; Iaccarino, G; Knoell, R; Leite-Moreira AF; Andre P Lourenco; Mayr, M; Thum, T; Tocchetti, CG
Tailoring mineralocorticoid receptor antagonist therapy in heart failure patients: are we moving towards a personalized approach? (2017)
Another Publication in an International Scientific Journal
Ferreira, JP; Mentz, RJ; Pizard, A; Pitt, B; Zannad, F

See all (88)

Recommend this page Top
Copyright 1996-2025 © Faculdade de Direito da Universidade do Porto  I Terms and Conditions  I Acessibility  I Index A-Z
Page created on: 2025-07-17 at 13:11:42 | Privacy Policy | Personal Data Protection Policy | Whistleblowing